Australia: A highly attractive environment for drug development

Australia offers a highly favorable environment for drug research and development, with a mature infrastructure and experienced, capable local resources and expertise. Considering global geopolitical uncertainties, Australia presents a compelling option for sponsors to consider. This first article in a three-part series illustrates the Australian economy, demographics, healthcare investments and expenditures, and the growth of the pharmaceutical market and clinical trials. Ensuing articles will explore the landscape for clinical trials, including the therapeutic areas, the strength of patient centricity and innovation adoption, and the regulatory and reimbursement environment.

Interested in more? Check out part 2 and part 3.


Open PDF

Return to Insights Center

Related Insights

Article

Can Chinese Phase I data from the West accelerate China drug development?

Mar 17, 2021

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Blog

Toward more inclusive studies: Reaching and retaining patients from underrepresented communities

Apr 25, 2022

Article

Six top tips to prepare for the new EU Clinical Trial Regulation

Apr 13, 2021

Webinar

In Conversation: Leadership Lessons on Diversity, Equity, & Inclusion, and the Future of Work

Apr 29, 2021

Video

Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Jun 8, 2021

Article

Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?

Jun 30, 2021

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Article

India, the Generic Manufacturing Powerhouse, Biosimilar Next?

Jul 21, 2021

Article

Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

Aug 6, 2021

Blog

Highlights from ISMPP Asia Pacific Meeting 2021

Sep 20, 2021

Article

3 ways to incorporate DE&I in your communications strategy

Sep 29, 2021

Related Insights

Article

Can Chinese Phase I data from the West accelerate China drug development?

Mar 17, 2021

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Blog

Toward more inclusive studies: Reaching and retaining patients from underrepresented communities

Apr 25, 2022

Article

Six top tips to prepare for the new EU Clinical Trial Regulation

Apr 13, 2021

Webinar

In Conversation: Leadership Lessons on Diversity, Equity, & Inclusion, and the Future of Work

Apr 29, 2021

Video

Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Jun 8, 2021

Show more